Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer

Raffone, Antonio; Travaglino, Antonio; Saccone, Gabriele; Cieri, Miriam; Mascolo, Massimo; Mollo, Antonio; Insabato, Luigi; Zullo, Fulvio

doi:10.1111/apm.12977

Cited by 42 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to technical difficulties and costs of sequencing analysis, a novel molecular classifier, the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), has been developed based on immunohistochemistry as surrogate of sequencing [2,6,8,9]. Immunohistochemistry is indeed more diffuse in the clinical practice because it is inexpensive and fast [10][11][12][13][14][15][16]. ProMisE classifies ECs in the following four prognostic groups: POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53wild-type (p53-wt).…”

Section: Introductionmentioning

confidence: 99%

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer

Raffone

Travaglino

Gabrielli

et al. 2021

Arch Gynecol Obstet

Self Cite

View full text Add to dashboard Cite

Background The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are still lacking. Objective To provide a clinical characterization of the ProMisE groups of EC. Methods A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to December 2020, for all studies reporting clinical characteristics of EC patients in each ProMisE group. Pooled means of age and BMI and pooled prevalence of FIGO stage I and adjuvant treatment in each ProMisE group were calculated. Results Six studies with 1, 879 women were included in the systematic review. Pooled means (with standard error) and prevalence values were: in the MMR-d group, age = 66.5 ± 0.6; BMI = 30.6 ± 1.2; stage I = 72.6%; adjuvant treatment = 47.3%; in the POLE-mt group, age = 58.6 ± 2.7; BMI = 27.2 ± 0.9; stage I = 93.7%; adjuvant treatment = 53.6%; in the p53-wt group, age = 64.2 ± 1.9; BMI = 32.3 ± 1.4; stage I = 80.5%; adjuvant treatment = 45.3%; in the p53-abn group, age = 71.1 ± 0.5; BMI = 29.1 ± 0.5; stage I = 50.8%; adjuvant treatment = 64.4%. Conclusion The ProMisE groups identify different phenotypes of patients. The POLE-mt group included the youngest women, with the lower BMI and the highest prevalence of stage I. The p53-wt group included patients with the highest BMI. The p53-abn group included the oldest women, with the highest prevalence of adjuvant treatment and the lowest prevalence of stage I. The MMR-d group showed intermediate values among the ProMisE groups for all clinical features.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer

Raffone

Travaglino

Gabrielli

et al. 2021

Arch Gynecol Obstet

Self Cite

View full text Add to dashboard Cite

show abstract

“…Besides, there may be some immunohistochemical factors in predicting EC in EH patients. AT-rich interaction domain 1A (ARID1A) loss in premalignant EH is an accurate and almost perfectly specific prognostic marker for coexistent cancer [45]. Besides, it's been found that PTEN loss in EH is a risk factor for EC, but is not reliable in predicting the risk of EC [46].…”

Section: Discussionmentioning

confidence: 99%

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Zhao¹,

Hu²,

Zhao

et al. 2021

BMC Women's Health

View full text Add to dashboard Cite

Background Endometrial hyperplasia (EH) is commonly-seen in the patients with endometrial cancer (EC), we aimed to evaluated the risk factors of EC in patients with EH, to provide evidence to the clinical prevention and treatment of EC. Methods This study was a retrospective study design. EH patients confirmed by pathological examinations and treated with hysterectomy in our hospital from June 1, 2018 to February 28, 2021 were included. The clinical characteristics of EC and no-EC patients were compared and analyzed. Logistics regression analyses were conducted to evaluate the risk factors of EC in patients with EH. Results A total of 228 EH patients were included, the incidence of EC in the EH patients was 31.58%. There were significant differences in the age, BMI, diabetes, hypertension and pathology of EH between EC and no EC groups (all P < 0.05), no significant differences in the hyperlipidemia, preoperative CA125, number of deliveries, menopause and endometrial thickness between EC and no EC groups were found (all P > 0.05). Logistic regression analyses indicated that age > 50 y (OR 3.064, 95% CI 1.945–5.931), BMI ≥ 25 kg/m2 (OR 2.705, 95% CI 1.121–3.889), diabetes (OR 3.049, 95% CI 1.781–5.114), hypertension (OR 2.725, 95% CI 1.108–3.431) and severe hyperplasia (OR 3.181, 95% CI 1.496–4.228) were the risk factors of EC in patients with EH (all P < 0.05). Conclusions The risk of EC in EH patients is high, especially for those patients with age > 50 y, BMI ≥ 25 kg/m2, diabetes, hypertension and severe hyperplasia, special attentions should be paid for occurrence of EC and early diagnosis and early treatment are needed for those patients.

show abstract

“…First, we only included premenopausal patients, who are the main candidates for conservative treatment. Second, we did not include non−atypical hyperplasia because it is considered a benign proliferation that lacks the typical mutations of AEH and EEC [1,2,23,24]. Third, all patients were treated with hysteroscopic resection plus LNG-IUD insertion, which may currently be the most effective conservative treatment for AEH and EEC [12].…”

Section: Strengths and Limitationsmentioning

confidence: 99%

Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion

Raffone¹,

Travaglino²,

Zullo³

et al. 2021

Journal of Minimally Invasive Gynecology

Self Cite

View full text Add to dashboard Cite

show abstract

Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer

Cited by 42 publications

References 39 publications

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion

Contact Info

Product

Resources

About